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Dear Editor,
Muscle contracture is a common symptom of valproate. However, 
there is no report in the literature of lockjaw (trismus) associated with 
this drug. We therefore present a case of lockjaw during valproate 
treatment in a patient with bipolar disorder and hypoparathyroidism.
A 62-year-old Caucasian female was admitted on November, 
2015 at a psychiatric unit during a manic episode. Patient was 
previously diagnosed with bipolar disorder and had manic and 
depressive episodes in the past. She underwent a total thyroidectomy 
three months prior to her admission, for suspicion of malignancy 
(not confirmed by biopsy) and has been since then in treatment 
for hypothyroidism and iatrogenic hypoparathyroidism with 
levothyroxine, calcitriol and calcium carbonate. She had no cognitive 
impairment and no relevant findings in laboratory exams. A cerebral 
perfusion scintigraphy was performed showing slight hypoperfusion 
in the frontal lobe and posterior cerebellar areas. It is noteworthy 
that the patient did not tolerate lithium carbonate due to severe 
extremity tremors. Therefore, valproate was initiated and gradually 
increased up to 1000 mg/day. She developed lockjaw three days after. 
She was unable to open her mouth and also fractured two teeth. She 
had difficulty in diction and in chewing food. No painful symptom 
or other muscular manifestation had been reported. Biperiden 
and clonazepam were prescribed without response. She had no 
prior symptoms of muscular spasm and she denied previous use of 
valproate. The diagnosis of valproate-induced trismus was made after 
other causes of trismus, such as infections, neurological illness and 
oro-dental abnormalities were excluded. The laboratory tests show 
no alterations on serum levels of TSH, PTH, phosphate and calcium. 
Thus, the valproate was replaced by olanzapine, which lead to 
symptom resolution. Patient has been in follow-up for two years and 
did not have any trismus symptoms since valproic acid withdrawal.
Trismus is defined as a tonic contraction of the muscles of 
mastication with mouth opening of ≤ 35 mm1. It can result in 
difficulty in activities such as biting, chewing, swallowing and 
speaking and may further lead to poor oral hygiene, pain and 
weight loss2. Some of the causal factors implicated in this condition 
are tumors, infections, surgery and radiotherapy complications, 
and drugs side effect3. There are case reports of trismus induced by 
succinylcholine4 and duloxetine5, but none regarding this side effect 
with valproate. A recent systematic review of the untoward effects 
of valproate showed that drug-induced parkinsonism is a relatively 
common side effect in elderly women6. It’s known that valproate can 
safely be used in patients with thyroid and parathyroid dysfunction, 
once it does not interfere on these hormone levels7. The mechanism of 
how valproate can induce trismus is unclear. A preclinical study found 
that low concentrations of valproate can induce muscle contractions, 
which were abolished by indomethacin.8 Therefore, prostaglandins 
may be implicated in the contractile effect of valproate8. 
In summary, the present study was the first to show a valproate-
induced trismus. This case report demonstrates that clinicians need to 
be vigilant for potential side effects after the beginning of a treatment 
with a psychoactive drug even when they are not reported in the 
scientific literature.
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